Home · Stock · GILD

GILD Gilead Sciences Inc

Which ETFs hold GILD? Gilead Sciences Inc is held by 2 funds tracked by ETFpeek.

Held by 2 funds todayData as of 31 Aug 2026
HealthcareDrug Manufacturers - General
$147.10
+28.6% 1y
$114.0252-week range$157.29
Market cap
$179.5B
Dividend
2.23%
3-month
+13.9%
CEO
Mr. Daniel Patrick O'Day
Revenue · last 4 qtrs (+10.2% YoY)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.

Provider

Currently Held By

VANGUARD
VOO
Weight in fund0.27%
Shares held32,985,031
Market value$4.83B
View fund →
SMARTSHARES
USF
Smart US 500 ETF
via VOO
Weight in fund0.27%
Shares held—
Market value$3.4M NZD
View fund →
Not held by the selected provider.
last 90 days
Net flow (90d):−$2.3M (1 without value)·1 BUY / 3 SELL·score ≥ 40
DatePersonActionPlanSharesValueScore i
1 Oct 2026
Daniel Patrick O'Day
Chairman & CEO
SELLUnknown12,000$1.8M60
Net flow (90d):−$2.3M (1 without value)·1 BUY / 3 SELL·showing all trades
DatePersonActionPlanSharesValueScore i
1 Oct 2026
Daniel Patrick O'Day
Chairman & CEO
SELLUnknown15,000
2 tranches
$2.2M60
22 Sep 2026
Erin Burkhart
Senior VP, Controller & Chief Accounting Officer
BUYOption Exercise2,223—0
22 Sep 2026
Erin Burkhart
Senior VP, Controller & Chief Accounting Officer
SELLVested (RSU)768$117K0
Data: Finnhub (SEC Form 4 filings) · Score: ETFpeek heuristic
0 trades
DateFundDirectionShares Changed% Δ ETF i% Δ Position i
No trades recorded yet.
No trade history for SmartShares funds — their underlying ETFs are passive index trackers, so day-to-day rebalancing is minimal.

More stocks in these funds